S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
LON:GENI

GENinCode (GENI) Share Forecast, Price & News

GBX 9.25
0.00 (0.00%)
(As of 10/3/2023 ET)
Compare
Today's Range
9.01
▼
9.40
50-Day Range
9.40
▼
13.28
52-Week Range
6.50
▼
26
Volume
85,000 shs
Average Volume
158,425 shs
Market Capitalization
£8.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsHeadlinesOptions Chain

GENI stock logo

About GENinCode (LON:GENI) Stock

GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.

GENI Price History

GENI Stock News Headlines

September 23, 2023 | americanbankingnews.com
GENinCode (LON:GENI) Shares Up 5.1%
August 16, 2023 | marketwatch.com
GENinCode Shares Rise on FDA Filing for Heart Disease Test Kit
October 3, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
July 19, 2023 | lse.co.uk
GENinCode and MedStar collaborate on coronary heart disease testing
July 19, 2023 | marketwatch.com
GENinCode Collaborates With MedStar Health for Coronary Heart Disease Test
July 14, 2023 | msn.com
Genetic testing could bring in ‘new age’ of diagnostics in NHS
June 6, 2023 | lse.co.uk
GENinCode annual loss widens; focuses on US, EU, and NHS in UK
May 21, 2023 | finance.yahoo.com
Should You Investigate Genius Sports Limited (NYSE:GENI) At US$5.18?
October 3, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
May 2, 2023 | lse.co.uk
UK National Health Service to hike use of GENinCode heart disease test
May 2, 2023 | marketwatch.com
GENinCode's Heart Disease Test Gets Accelerated Use in UK; Shares Rise
January 3, 2023 | lse.co.uk
GENinCode shares surge amid state licence approval for California lab
October 21, 2022 | finance.yahoo.com
Genius Sports (NYSE:GENI) shareholders have endured a 78% loss from investing in the stock a year ago
September 29, 2022 | lse.co.uk
EARNINGS UPDATES: Transence Tech swings to profit; Curzon widens loss
August 5, 2022 | ca.finance.yahoo.com
GENinCode plc (GENI.L)
July 8, 2022 | uk.investing.com
Shenzhen Techwinsemi Technology Co Ltd (001309)
July 8, 2022 | uk.investing.com
Nordic Lights Group Oy (NORDLIG)
July 3, 2022 | lse.co.uk
Das (RBI): "Cryptocurrencies are a clear danger, their value is based on fantasy"
July 3, 2022 | lse.co.uk
UPDATE: Braemar Shipping delays publication of results; outlook good
See More Headlines
Receive GENI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GENinCode and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:GENI
CUSIP
N/A
CIK
N/A
Web
www.genincode.com
Phone
44 1865 955 847
Fax
N/A
Employees
34
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-6,730,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-84.23%
Return on Assets
-43.64%

Debt

Debt-to-Equity Ratio
6.74
Current Ratio
5.92
Quick Ratio
15.89

Sales & Book Value

Annual Sales
£1.72 million
Price / Sales
5.15
Cash Flow
GBX 11.10 per share
Price / Cash Flow
0.83
Book Value
GBX 5 per share
Price / Book
1.85

Miscellaneous

Outstanding Shares
95,820,000
Free Float
N/A
Market Cap
£8.86 million
Optionable
Optionable
Beta
0.64
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Matthew Heaton Walls (Age 59)
    Co-Founder, CEO & Director
    Comp: $336.54k
  • Mr. Jordi Puig Gilberte
    Co-Founder, COO & Director
  • Mr. Paul Andrew Peter Foulger (Age 53)
    CFO, Company Sec. & Director
    Comp: $150.07k

Key Competitors

View All Competitors













GENI Stock - Frequently Asked Questions

How have GENI shares performed in 2023?

GENinCode's stock was trading at GBX 7.75 at the beginning of 2023. Since then, GENI stock has increased by 19.4% and is now trading at GBX 9.25.
View the best growth stocks for 2023 here.

What is GENinCode's stock symbol?

GENinCode trades on the London Stock Exchange (LON) under the ticker symbol "GENI."

How do I buy shares of GENinCode?

Shares of GENI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is GENinCode's stock price today?

One share of GENI stock can currently be purchased for approximately GBX 9.25.

How much money does GENinCode make?

GENinCode (LON:GENI) has a market capitalization of £8.86 million and generates £1.72 million in revenue each year. The company earns £-6,730,000.00 in net income (profit) each year or GBX (0.06) on an earnings per share basis.

How can I contact GENinCode?

GENinCode's mailing address is Oxford Science Park, John Eccles House Robert Robinson Avenue, Oxford OX4 4GP, United Kingdom. The official website for the company is www.genincode.com. The company can be reached via phone at 44 1865 955 847.

This page (LON:GENI) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -